Drug intelligence / Profile preview

paroxetine + benzodiazepine

Development stage
Unknown
Lead developer
GSK
Modality
Small Molecules
Administration
Oral
01

Overview

Paroxetine + benzodiazepine refers to the co-administration of paroxetine, a selective serotonin reuptake inhibitor (SSRI), with any drug from the benzodiazepine class. Paroxetine acts primarily as a serotonin transporter inhibitor, thereby increasing synaptic serotonin levels to treat depression, anxiety disorders, and panic disorder. Benzodiazepines (such as alprazolam, diazepam, or clonazepam) are central nervous system depressants that act as positive allosteric modulators of the gamma-aminobutyric acid (GABA) type A receptor, enhancing GABAergic inhibition to provide anxiolytic, sedative, and muscle relaxant effects. The combination is sometimes used clinically for rapid anxiety or panic relief, but carries a risk of additive CNS depression, including excess sedation, cognitive impairment, and, in cases of overdose, potentiation of toxicity and respiratory depression[1][2][3][4][5][7][8].

Brand names
Paxil + class of benzodiazepine drugs
Other names
paroxetine + benzodiazepinePaxil + benzodiazepine
02

Targets

SERT (Sodium-dependent serotonin transporter)GAT2 (Sodium- and chloride-dependent GABA transporter 2)GABRR (GABA-A receptor subunit rho)GAT-3 (Sodium- and chloride-dependent GABA transporter 3)BGT1 (Betaine/GABA transporter 1)SLC6A1 (Sodium- and chloride-dependent GABA transporter 1)NET (Norepinephrine Transporter)

Beyond the preview

Go deeper on paroxetine + benzodiazepine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on paroxetine + benzodiazepine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call